Argos Therapeutics, Inc. ARGS
At closeJun 28, 2019, 6:07 PM EDT
- Revenue (ttm)
- 7.71M
- Profit margin
- -214.59%
- Shares out
- 10.59M
- Forward P/E
- -0.02
- Volume
- 758.98K
- Avg volume
- 2.63M
- Open
- 0.265
- Previous close
- 0.2701
- Day's range
- 0.25 – 0.2849
- 52-week range
- 0.1251 – 3.89
- Beta
- -0.49
- Analysts
- Hold
- Price target
- 0.75 (+177.7%)
Key statistics
- Enterprise value
- 8.19M
- PEG ratio
- 0.00
- Price / sales
- 0.19
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -22.20%
- Free cash flow
- -7.43M
- Total cash
- 12.13M
- Total debt
- 18.94M
- Return on equity
- 0.00%
- Short % of float
- 9.57%
- 50-day average
- 0.144417
- 200-day average
- 0.147355
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 22, 2017 | Needham | down | — | Hold |
| Mar 25, 2015 | Roth Capital | init | — | Buy |
| Feb 24, 2015 | MLV & Co. | init | — | Buy |
| Mar 3, 2014 | Stifel Nicolaus | init | — | Buy |
About Argos Therapeutics, Inc.
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- argostherapeutics.com
News
Your note
Sign in to keep a note on ARGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABBEY JEFFREY D | Chief Executive Officer | Stock Award(Grant) | Mar 27, 2018 | 93,337 |
| ALLEN LEE F | Officer | Stock Award(Grant) | Jan 18, 2017 | 7,378 |
| BIRNER HUBERT | Director | Stock Award(Grant) | Dec 29, 2016 | 12,680 |
| CAREY ROBERT F. | Director | Stock Award(Grant) | Dec 29, 2016 | 8,206 |
| HARRELSON LORI R | Officer | Stock Award(Grant) | Mar 27, 2018 | 34,405 |
| KATZ RICHARD D | Chief Financial Officer | Stock Award(Grant) | Mar 27, 2018 | 32,326 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Pharmstandard International S.A. | 7.80% | 826,153 | 136.31K | Jun 29, 2018 |
| Wedbush Securities Inc | 0.74% | 78,000 | 12.87K | Jun 29, 2018 |
| Meeder Asset Management, Inc. | 0.05% | 5,671 | 935 | Jun 29, 2018 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 9.76% | 1,033,736 | 3.10M | Dec 30, 2017 |
| Wasatch Ultra Growth Fund | 4.85% | 513,577 | 1.54M | Dec 30, 2017 |
| Meeder Funds-Spectrum Fund | 0.21% | 22,439 | 67.32K | Dec 30, 2017 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.04% | 3,850 | 11.55K | Dec 30, 2017 |
| Vanguard Balanced Index Fund | 0.03% | 3,200 | 9.60K | Dec 30, 2017 |
| Invesco ETF Tr-Invesco Wilshire Micro Cap ETF | 0.03% | 2,872 | 473 | Jun 29, 2018 |